Skip to main content

Table 19 (Abstract P249). See text for description

From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two

 

PharMetrics

MarketScan

Baseline characteristics

Abatacept n = 91

Other bDMARDs n = 3934

Abatacept n = 137

Other bDMARDs n = 3559

Female

79 (86.8)*

2820 (71.7)*

119 (86.9)*

2607 (73.3)*

Age, mean (SD)

13.4 (3.0)*

11.2 (4.2)*

12.6 (3.2)*

11.4 (4.2)*

Hospitalized infections

3 (3.3)

128 (3.3)

5 (3.7)

81 (2.3)

Uveitis

3 (3.3)*

434 (11.0)*

10 (7.3)

420 (11.8)

Non-bDMARDs

43 (47.3)

2063 (52.4)

37 (27.0)*

1801 (50.6)*

Treatment pattern

Switching to non-bDMARD

Discontinuing

Staying on abatacept or index bDMARD

Switching to other bDMARD

34 (37.4)

6 (6.6)

35 (38.5)*

16 (17.6)

1727 (43.9)

362 (9.2)

1114 (28.3)*

731 (18.6)

41 (29.9)*

14 (10.2)

62 (45.3)*

20 (14.6)

1680 (47.2)*

364 (10.2)

948 (26.6)*

567 (15.9)

  1. Data are n (%) unless indicated otherwise
  2. *p < 0.05 for the difference between the two treatment groups in each of the two databases